Podcasts about circulating

Cancer, cardiovascular disease, diabetes, mold toxicity, parasites, and chronic illness are often treated as separate problems—but what if they all stem from the same root cause? David DeHaas, founder of Living Waters Wellness Center, sits down with Alicia Hickson, PA-C, founder of Rama Health, to explore why cancer is not primarily a genetic disease, but a metabolic and mitochondrial disorder driven by inflammation, toxins, mold exposure, parasites, blood sugar dysregulation, emotional trauma, and impaired detoxification pathways.Drawing from the groundbreaking research of Dr. Thomas Seyfried, Alicia explains how damaged mitochondria alter cellular energy production, creating an internal environment where cancer and chronic disease can thrive. This conversation challenges the conventional genetic theory of cancer and reframes healing through the lens of terrain medicine.Throughout the episode, David and Alicia connect the dots between:Mitochondrial dysfunction and cancer metabolismMold toxicity, candida, yeast, and immune system overloadParasites and chronic inflammationEmotional trauma, unforgiveness, and limbic system dysregulationConstipation, lymphatic congestion, and impaired detox pathwaysWhy genetics account for only a small percentage of disease riskWhy conventional medicine often misses root causesWhen integrative and conventional medicine work best togetherDavid shares compelling real-world cases from Living Waters Wellness Center, including parasite cleansing, colon hydrotherapy, emotional release, and rapid shifts in tumor presentation—demonstrating how healing accelerates when the body's internal terrain is restored.Alicia also breaks down advanced clinical tools and therapies, including:Circulating tumor cell testing for cancer monitoringHormone metabolism and estrogen detox pathways (DUTCH testing)Mold and mycotoxin testing strategiesHyperthermia therapy, mistletoe therapy, and immune modulationWhy maintaining remission is just as important as treating cancerThis episode is essential listening for anyone who has been told, “There's nothing more we can do,” aSupport the show Ready for your healing journey?Visit our website: www.LivingWatersCleanse.com Or give us a call at: (208) 378-9911Stem Cell Activation Patches:www.StemCellPatch.netGet your Supplements and Natural Body Products Here:www.livingwaterscleanse.com/supplementsQI-Shield EMF Devices:Protect your whole home or office with a touric shield from EMF's. 1. QI Shield Covers 16'x16' 2. QI Home Covers 50' x 50' 3. QI Max Covers 250'x250'Click on link and enter Livingwaters in discount code section during checkout Magnesium Soaks:Follow us on our socials: Living Waters Wellness CenterBitChute: www.bitchute.com/livingwaterswellnessRumble: www.rumble.com/l...

A new version of the common flu is spreading globally, and health officials are monitoring this evolving strain of influenza A which has been increasingly detected worldwide. In other news, It's official: McKinney National Airport has its first airline. Avelo Airlines, the Houston-based budget carrier, signed a five-year use and lease agreement, the airport said Tuesday evening; Dallas Mavericks owner and casino magnate Miriam Adelson urged President Donald Trump to run for a third term in 2028; nd Romeo Santos and Prince Royce will perform together for the first time in Dallas next spring as part of their “Mejor Tarde Que Nunca” tour. In Dallas, they will perform on Saturday, May 9, at American Airlines Center. Tickets go on sale this Friday, Dec. 19. Learn more about your ad choices. Visit podcastchoices.com/adchoices

(SPOILER) Your Daily Roundup covers Taylor Frankie Paul's final week of filming, the Blake Moynes story circulating, tomorrow's live re-watch on the Patreon channel, & Rob Reiner's directorial run from the mid 80's to early 90's.    Music written by Jimmer Podrasky (B'Jingo Songs/Machia Music/Bug Music BMI) Ads: ZocDoc – Click on https://zocdoc.com/RealitySteve to find and instantly book a top rated doctor today.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Former high-school teacher turned hypnotherapist, DJ, and three-time spiritual entrepreneur, Anna Cantwell shares how she went from burnout and "can't-pay-rent" panic to making great money doing work she loves—by prioritizing receiving, play, and ease. We dig into Hot Money Summer–style prompts, why compliments are cash practice, and practical ways to circulate stuck energy so abundance can find you. In this conversation From broke, sick, and overworked to six figures in 15 hours/week—what changed (and what didn't). Why "hard work = money" breaks down—and the feminine side of receiving. The Zone of Proximal Development for money mentors (learning from someone just ahead of you). Fun, fast exercises: "Hot Money Bummers → Wouldn't It Be Nice…," playful income reframes, and saying "thank you, I receive that." Circulating energy: clothing swaps, donating, and finding the money you forgot you had. Book sneak peek: Abundance Mindset Magic—the fun, feminine & magical way to manifest money and open yourself to receive. Try-it-now prompts Compliment practice: For 7 days reply, "Thank you—I receive that." Notice what shifts. Reframe your income: Write the funnest way to describe how you currently make money—and one way you'd love to. Clear & circulate: Unused items → swap/donate to create space for new inflow.  Connect with Anna Book: Abundance Mindset Magic (available via major booksellers). IG: @iamannacantwell Connect with Jen Join the Manifestation Playground Instagram → @manifestationandmoneypodcast Cheers to creating a life you love!

Commentary by Dr. Peter van der Meer.

Dr. Juan Carlos Samamé, oncólogo médico de Lima, Perú, y vicepresidente de la Latin American Breast Cancer Association (LABCA), recibe al Dr. Antonio Llombart Cussac, jefe de servicio en el Hospital Arnau de Vilanova y coordinador en la Universidad Cardenal Herrera en Valencia, España. Juntos nos hablan sobre lo mejor en cáncer de mama, presentado en el marco del Simposio de Cáncer de Mama de San Antonio 2025, celebrado del 9 al 12 de diciembre de 2025 en San Antonio, Texas, Estados Unidos.Cáncer de mama luminal:lidERA Breast Cancer [1]EPIK-B5 [2]Cáncer de mama HER2:PHERGain [3] CLEOPATRA[4]PATINA[5]HER2CLIMB-05[6]ALTTO[7]Referencias:Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative early breast cancer: Results from the global Phase III lidERA Breast Cancer trial. https://sabcs.org/events/general-session-1/. Presentación científica (Abstract GS1-10). Presentado en el marco del Simposio de Cáncer de Mama de San Antonio 2025, celebrado del 9 al 12 de diciembre de 2025 en San Antonio, Texas, Estados Unidos.De Laurentiis M., Ferreira A. M., Gligorov, J., y cols. (2025, diciembre 9–12). Alpelisib plus fulvestrant for PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer after a CDK4/6 inhibitor (EPIK-B5): Phase III, randomized, double-blind, placebo-controlled, multicenter study (Abstract RF7-02). Presentado en el marco del Simposio de Cáncer de Mama de San Antonio 2025, celebrado del 9 al 12 de diciembre de 2025 en San Antonio, Texas, Estados Unidos.Llombart-Cussac, A., Pérez-García, J., Ruiz-Borrego., y cols. Circulating tumor DNA (ctDNA) in human epidermal growth factor receptor 2-positive (HER2[+]) Early Breast Cancer (EBC): Translational analysis of PHERGain neoadjuvant tailored treatment study (Abstract GS1-06). Presentado en el marco del Simposio de Cáncer de Mama de San Antonio 2025, celebrado del 9 al 12 de diciembre de 2025 en San Antonio, Texas, Estados Unidos.Rinnerthaler, G., Gampenrieder, S. P., Pichler, A., y cols. Clinical predictors for first-line treatment duration in HER2-positive metastatic breast cancer: Results from the AGMT_MBC-Registry. AGMT_MBC-Registry study (Abstract PS5-01-04). Presentado en el marco del Simposio de Cáncer de Mama de San Antonio 2025, celebrado del 9 al 12 de diciembre de 2025 en San Antonio, Texas, Estados Unidos.Metzger, O., Mandrekar, S., & Dockter, T. (2025, December 9–12). Central nervous system outcomes from the Phase III PATINA trial (AFT-38) (Abstract RF4-01). Presentado en la San Antonio Breast Cancer Symposium (SABCS) 2025; del 09 al 12 de diciembre de 2025; San Antonio, Texas.Hamilton E., Curigliano G., Martin M., y cols (2025). HER2CLIMB-05: A randomized, double-blind, phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer. Abstract GS1-01. Presentado en el marco del Simposio de Cáncer de Mama de San Antonio 2025, celebrado del 9 al 12 de diciembre de 2025 en San Antonio, Texas, Estados Unidos.Lambertini M, Samy F, Agostinetto E y cols. Adjuvant aromatase inhibitor or tamoxifen in patients with hormone receptor-positive/HER2-positive early breast cancer: An exploratory analysis from the ALTTO (BIG 2-06) trial. Abstract #GS1-03. Presentado en la San Antonio Breast Cancer Symposium (SABCS) 2025; del 09 al 12 de diciembre de 2025; San Antonio, Texas. Abstract GS1-09.

Bailing out Santa, one season at a time, It's Circulating the Tapes, the MST3K watchalong podcast on The Aewchcast. On this Xmas Xtravaganza episode, Aewch may have to burn his passport, as he reviews The Christmas That Almost Wasn't!Watch The Christmas That Almost Wasn't Right Here!The CTT UERL Top Ten!I Accuse My ParentsGodzilla vs MegalonMaster Ninja 1Santa Claus Conquers the MartiansAvalancheWerewolfThe StarfightersTeenage StranglerSwamp DiamondsPrince of SpaceSocial Media: @JustAewchEmail: aewch64@gmail.com

It's that Septober season on Circulating the Tapes, the MST3K Watchalong podcast on The Aewchcast. On this Xmas Xtravaganza episode, Aewch wonders what Santa was smoking, as he reviews Santa Claus Conquers the Martians!Watch Santa Claus Conquers the Martians Right Here!The CTT UERL Top Ten!I Accuse MY ParentsGodzilla vs MegalonMaster Ninja 1AvalancheWerewolfThe StarfightersTeenage StranglerSwamp DiamondsPrince of SpaceZombie NightmareSocial Media: @JustAewch Email:aewch64@gmail.com

Brock and Salk talk through the elements of what makes a team a Super Bowl team and how much of it the Seahawks have on their roster. They then look at a handful of names that the Mariners could trade for, especially with the MLB Winter Meetings coming up next week. In Blue 88, Brock analyzes more on the Seahawks culture, Mike Macdonald discussing the Vikings defense and the University of Colorado athletic department.

Insp. Glenn Smith provides the latest Murrumbidgee Police District Update Tuesday mornings during Brekkie after 7.See omnystudio.com/listener for privacy information.

It's not too late- come join us all week long in our BEST YEAR YET training! Happening Monday Nov 24th-Friday Nov 28th: https://www.myalignedpurpose.com/bestyearIn this TGIM, Nicole gets real about a belief many of us were taught growing up, that saving is the only way to get rich. Inside entrepreneurship, the truth is different. Wealth grows through circulation, investment, and proximity, not by waiting for the perfect time.You will hear how money is energy, why mentorship collapses time, and how community accelerates sustainable business growth. Nicole shares lived examples, from investing in high-level coaching to choosing structure over hesitation, so you can stop waiting and start growing your aligned business now.If you want a richer life and a profitable company that feels good, this conversation shows you how strategy meets soul, and how the right coaching, community, and money mindset unlock 6-figure momentum.Key takeawaysYou cannot save your way to wealth. Wealth for women entrepreneurs grows through circulating money, smart investments, and business mentorship, not by hoarding cash.Waiting keeps you stuck. Accountability and coaching collapse years into months, helping you scale your business with clarity and confidence.Proximity is a growth strategy. Being in the room with high-achieving women expands what you believe is possible and upgrades your money mindset and standards.Invest before you feel ready. Big moves, like joining a mastermind or hiring a coach, create commitment, action, and sustainable business growth.Strategy meets soul wins. Pair aligned strategy with energetic alignment, and watch your 6-figure business growth become inevitable.Join Jess Marley from the Local Inc. at the Jingle and Mingle Party, Dec. 4th at the Queen's in Nanaimo, BC. Tickets available here: https://thelocalinc.ca/product/the-not-so-corporate-christmas-party/Mentioned in this episode:Ready to have your BEST YEAR YET?Join us for five days of mindset, money, and strategy magic where we'll walk you through how to plan your most aligned, abundant year yet! Monday Nov 24th - Friday Nov 28th WE GATHER DAILY 3-4 pm pst (virtually on zoom) You're a woman in business with big goals your own clients, more cash flow, more freedom But if you're honest… sometimes you're flying by the seat of your leggings. You want to enter 2026 feeling focused and in control because as of right now

Kotax repeal Petitions are circulating so contact the team to get them so you can join the fun! https://stopthegastax.com/ Salem urinal fishwrap paper tries to spin the repeal effort: https://www.statesmanjournal.com/story/news/politics/2025/11/13/oregon-gas-tax-referendum-effort-to-begin-collecting-signatures/87198690007/?gnt-cfr=1&gca-cat=p&gca-uir=true&gca-epti=z116928p001350c001350d00----v116928b0069xxd116965&gca-ft=113&gca-ds=sophi&tbref=hp Rumor is Kotax fled to Hawaii so no media can ask her daming questions about the repeal effort: https://oregoncatalyst.com/92277-rumor-gov-kotek-left-hawaii.html ORTL wins big in 9th Circus Court of Appeals. https://oregoncatalyst.com/92305-oregon-life-wins-ninth-circuit.html Judge says ICE random license plate checks that lead to detentions are illegal: https://www.oregonlive.com/crime/2025/11/ices-random-license-plate-checks-in-oregon-lead-to-unlawful-detention-judge-says.html NV Supreme court reopens Trump 2020 electors criminal case despite Trump pardons: https://www.thegatewaypundit.com/2025/11/nevada-supreme-court-revives-trump-2020-alternate-electors/  

In this episode of the Wise Divine Women podcast, Dana Irvine and Dr. John Oertle discuss the latest advancements in breast cancer research, focusing on recurrence rates, the role of circulating tumor cells, and the importance of optimizing the immune system. Dr John's main goal is to enlighten Americans and people worldwide that there is a groundbreaking study published in Nature is shining a light on a hidden risk: respiratory infections can reawaken dormant breast cancer cells, accelerating recurrence. Read the article and research links They explore the impact of environmental toxins on cancer, the necessity of early detection through testing, and the effects of respiratory infections on cancer patients. The conversation also touches on the role of vaccines in immune response and the potential future of peptides in cancer treatment, emphasizing the need for advocacy in accessing innovative therapies.Envita Medical Center Want to listen to our first episode together? Wise Divine Women podcast, host Dana Irvine speaks with Tammy Morrow and Dr. John Oertle about the intersection of faith, health, and innovative cancer treatmentsTakeawaysRecurrence rates for stage one breast cancer can be as high as 20-30%.Circulating tumor cells can be detected even in early-stage cancers.Optimizing the immune system is crucial for cancer patients.Environmental toxins may trigger cancer development.Testing for circulating tumor cells can aid in early detection.Respiratory infections can impact cancer recurrence and growth.Vaccines may enhance immune response in cancer treatment.Peptides show promise in cancer treatment but require careful dosing.Advocacy for access to innovative treatments is essential.Education and awareness are key for patients in managing their health.Chapters00:00 Introduction to Breast Cancer Research01:04 Understanding Recurrence Rates in Breast Cancer03:51 The Role of Circulating Tumor Cells09:38 Maximizing Outcomes Through Immune System Support17:18 Challenges in Oncology: Insurance and Testing21:20 Environmental Toxins and Cancer Prevention23:43 Impact of Respiratory Infections on Cancer25:15 The Role of IL-6 in Cancer Growth28:25 Monitoring Cancer Recurrence Post-Infection29:37 Vaccines and Immune Response33:14 Immunotherapy and Immune System Dynamics37:45 The Future of Peptides in Cancer Treatment46:05 Access to Preventive HealthcareI hope you enjoyed this episode! Please leave a review and share with friends and family Want to learn more about my offerings? Please visit danairvine.com I invite you to schedule a Soul Session to lern about how we can work together or dive right in and book a Women's Hormone Transformation

Send us a textHow mitochondria travel between cells and how this hidden communication shapes metabolism, immunity, and even potential therapies.Episode Summary: Dr. Jon Brestoff talks about mitochondrial dynamics inside cells, their transfer between unrelated cells (distinct from inheritance during division), and its roles in adipose tissue communication, macrophage cleanup, and systemic metabolic signaling; they explore how high-fat diets disrupt this process, potential hormetic benefits, therapeutic mitochondria transplantation for diseases like Leigh syndrome and obesity, and broader immunometabolism crosstalk.About the guest: Jon Brestoff, MD, PhD is an associate professor of pathology and immunology at Washington University School of Medicine in St. Louis, where he directs the Initiative for Immunometabolism.Discussion Points:Mitochondria per cell range from ~100-5000; they move via fusion/fission, vertical inheritance (cell division), or horizontal transfer without division.Transfer mechanisms: free release, extracellular vesicles, or tunneling nanotubes using cytoskeleton transport.In healthy fat tissue, adipocytes routinely donate mitochondria to macrophages for degradation (quality control); high-fat (lard-based, long-chain FA) diets block macrophage uptake, diverting mitochondria to other organs.Diverted mitochondria may induce “mito-hormesis” (mild oxidative stress boosting antioxidants) or signal adipocyte metabolic status inter-organ.Mitochondria transplantation shows promise in animal models for ischemia-reperfusion, obesity, and mitochondrial diseases.Immune cells prefer glycolysis but have low mitochondrial biomass; transplanted mitochondria tilt T-cells toward anti-inflammatory regulatory phenotype.Circulating cell-free mitochondria rival immune cell numbers.Obesity inflammation stems from dying oversized adipocytes releasing lipids/mitochondria, forming crown-like structures with pro-inflammatory macrophages.Leigh syndrome from genetic mutations disrupting the electron transport chain.Transfer may be an evolutionary relic of endosymbiosis; cells may selectively use exogenous mitochondria like a “generator” during metabolic crisis.Reference Paper:Study: The power and potential of mitochondria transferRelated Episode:M&M 260: Energy Resistance Principle in Life, Healing & Disease | Martin Picard & Nirosha MuruganSupport the showAffiliates: Seed Oil Scout: Find restaurants with seed oil-free options, scan food products to see what they're hiding, with this easy-to-use mobile app. KetoCitra—Ketone body BHB + electrolytes formulated for kidney health. Use code MIND20 for 20% off any subscription (cancel anytime) Lumen device to optimize your metabolism for weight loss or athletic performance. Code MIND for 10% off SiPhox Health—Affordable at-home blood testing. Key health markers, visualized & explained. Code TRIKOMES for a 20% discount. For all the ways you can support my efforts

In Running on Empty: Circulating on Fumes, The Ten Minute Medic trades sirens for subtlety—reminding us that not all emergencies come screaming. Our unlucky protagonist is a pregnant patient whose body has turned “morning sickness” into an Olympic event, leaving her so dehydrated her cardiovascular system is basically running on fumes. This episode turns a quiet case of hyperemesis gravidarum into a masterclass on spotting shock before it strikes. It's equal parts physiology refresher and paramedic pep talk—complete with the gentle reminder to be good humans to our patients...especially when they are making a new human!

Yesterday at the Madlanga Commission, Brigadier Mishak Mkhabela highlighted how understaffed Saps ballistics units and circulating firearms are fueling violent crime. Africa Melane speaks to Dr. Stanley Maphosa from Gun Free South Africa on the urgent need for stronger gun control and justice. Early Breakfast with Africa Melane is 702’s and CapeTalk’s early morning talk show. Experienced broadcaster Africa Melane brings you the early morning news, sports, business, and interviews politicians and analysts to help make sense of the world. He also enjoys chatting to guests in the lifestyle sphere and the Arts. All the interviews are podcasted for you to catch-up and listen. Thank you for listening to this podcast from Early Breakfast with Africa Melane For more about the show click https://buff.ly/XHry7eQ and find all the catch-up podcasts here https://buff.ly/XJ10LBU Listen live on weekdays between 04:00 and 06:00 (SA Time) to the Early Breakfast with Africa Melane broadcast on 702 https://buff.ly/gk3y0Kj and CapeTalk https://buff.ly/NnFM3N Subscribe to the 702 and CapeTalk daily and weekly newsletters https://buff.ly/v5mfetc Follow us on social media: 702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/Radio702 702 on YouTube: https://www.youtube.com/@radio702 CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

Even a Shamwow thinks this movie is too wet, it's Circulating the Tapes, the MST3K watchalong podcast on The Aewchcast. On this final Halloweenie episode, Aewch would prefer the jacuzzi scene, as he reviews Revenge of the Creature.Watch Revenge of the Creature…on your copy of the DVD! *Cough* righthere! *Cough*The CTT UERL Top Ten!I Accuse MY ParentsGodzilla vs MegalonMaster Ninja 1AvalancheWerewolfThe StarfightersTeenage StranglerSwamp DiamondsPrince of SpaceZombie NightmareSocial Media:@JustAewchEmail: aewch64@gmail.com

This is absolutely fascinating, it's Circulating the Tapes, the MST3K watchalong podcast on the Aewchcast.  On this Halloweenie episode, Aewch wonders if they offer werewolf training, as he reviews Werewolf.Watch Werewolf Right Here!The CTT UERL Top 10!I Accuse My ParentsGodzilla vs MegalonMaster Ninja 1AvalancheThe StarfightersTeenage StranglerSwamp DiamondsPrince of SpaceZombie NightmareSquirmSocial Media:@JustAewchEmail: aewch64@gmail.com

En esta cápsula de ESMO 2025 EXPRESS, el Dr. Mariano Dioca, oncólogo médico adscrito al Instituto de Oncología Ángel H. Roffo en Buenos Aires, Argentina, nos habla sobre las principales novedades en tumores gastrointestinales, destacando cuatro estudiosrelevantes:El estudio PHERFLOT (fase II) evaluó pembrolizumab y trastuzumab en combinación con FLOT frente FLOT en pacientes HER2-positivos con cáncer gástrico o de la unión esofagogástrica. El PERISCOPE II (fase III) analizó la citorreducción peritoneal más HIPEC en cáncer gástrico avanzado, sin demostrar beneficio en supervivencia global.El CITRIC (fase II) exploró el retratamiento con cetuximab + irinotecán frente a terapia estándar (sin inhibidores de EGFR). Finalmente, el PARERE (fase II) comparó las secuencias panitumumab-regorafenib versus regorafenib-panitumumab en el contexto de rechallenge anti-EGFR. 4En conjunto, estos estudios aportan evidencia relevante sobre el papel del rechallenge anti-EGFR y las estrategias inmuno-quimioterápicas en cáncer gástrico y colorrectal avanzado. Referencias:Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive localized esophagogastric adenocarcinoma: Interim analysis of the phase II PHERFLOT/IKF-053 trial of the AIO study group (AIO STO 0321). Abstract # 2095MO, presentado en el marco del Congreso Anual de la Sociedad Europea de Oncología Médica (ESMO®) 2025, celebrado del 17 al 21 de octubre de 2025 en Berlín, Alemania.Systemic therapy, gastrectomy and CRS/HIPEC vs systemic therapy alone for gastric cancer with limited peritoneal dissemination: Results of the randomised PERISCOPE II trial. Abstract #2096MO, presentado en el marco del Congreso Anual de la Sociedad Europea de Oncología Médica (ESMO®) 2025, celebrado del 17 al 21 de octubre de 2025 en Berlín, Alemania.Circulating tumor (ct) DNA-guided anti-EGFR rechallenge strategy in metastatic colorectal cancer (mCRC): Final results of the phase II randomized CITRIC trial. Abstract #LBA33, presentado en el marco del Congreso Anual de la Sociedad Europea de Oncología Médica (ESMO®) 2025, celebrado del 17 al 21 de octubre de 2025 en Berlín, Alemania.Panitumumab retreatment followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA (ctDNA): Final results of the randomized PARERE trial by GONO. Abstract #LBA32, presentado en el marco del Congreso Anual de la Sociedad Europea de Oncología Médica (ESMO®) 2025, celebrado del 17 al 21 de octubre de 2025 en Berlín, Alemania.Fecha de grabación: 18 de octubre de 2025 Material exclusivo para profesionales de la salud. Estematerial ha sido desarrollado únicamente con fines educativos e informativos y no tiene la intención de sustituir el juicio clínico de los profesionales de la salud. Las opiniones y declaraciones presentadas en este contenido son responsabilidad exclusiva de los ponentes y no reflejan necesariamente la postura institucional de ScienceLink ni de terceros mencionados. La información presentada se basa en el conocimiento y la experiencia profesional de los ponentes. La veracidad, exactitud y actualidad científica de los datos son de su exclusiva responsabilidad. Así mismo garantizan que el contenido utilizado no infringe derechos de autor de terceros y asumen toda responsabilidad por su uso. Se deberán de revisar las indicaciones aprobadas en el país con estricto apego al marco regulatorio aplicable para cada uno de los tratamientos y medicamentos comentados.  ESMO® es una marca registrada de la European Society ForMedical Oncology. Este material ha sido producido de manera independiente y no está autorizado, patrocinado ni avalado por dicha organización.

Jason Kelce sets the record straight regarding some fake viral statements he never actually made. Plus, his brother Travis may be involved in a shade war between his fiance and his ex-gf. And, the Dodgers take a 2-0 series lead i the NLCS behind a pitcher that did something you don't see every day. Learn more about your ad choices. Visit podcastchoices.com/adchoices

The Drive is starting to hear report that Chiefs OC Matt Nagy could be hired by the Tennessee Titans.

A Metaphysician doesn't believe you can podcast when you're dead. It's Circulating the Tapes, the MST3K watchalong podcast on The AewchCast. On this Halloweenie episode, it's like playing an even more boring version of Clue, as Aewch reviews The Dead Talk Back. Plus, the company that makes Budweiser wants to sell you a freezer in The Selling Wizard.Watch The Dead Talk Back Right Here! The CTT UERL Top 10!I Accuse My ParentsGodzilla vs MegalonMaster Ninja 1AvalancheThe StarfightersTeenage StranglerSwamp DiamondsPrince of SpaceZombie NightmareSquirmSocial Media: @JustAewchEmail: aewch64@gmail.com

Patrick Kenny, Commission Member with the CCPC, highlights the Tucson products which are installed in home heating systems that the CCPC have issued an urgent safety alert over.

The only burger joint out of brains, it's Circulating the Tapes, the MST3K watchalong podcast on The Aewchcast. On this first Halloweenie episode, it's a basic zombie movie, but Tia Carrera had to start somewhere, as Aewch reviews Zombie Nightmare.Watch Zombie Nightmare Right Here!The CTT UERL Top Ten!I Accuse My ParentsGodzilla vs MegalonMaster Ninja 1AvalancheThe StarfightersTeenage StranglerSwamp DiamondsPrince of SpaceSquirmThe Million Eyes of SumuruSocial Media: @JustAewchEmail: aewch64@gmail.com

Always wear a helmet in the wasteland, it's Circulating the Tapes, the MST3K watchalong podcast on the Aewchcast. On this episode, Aewch is more of a Fallout guy himself, as he reviews Warrior of the Lost World.Watch Warrior of the Lost World Right Here!The CTT UERL Top Ten!I Accuse My ParentsGodzilla vs MegalonMaster Ninja 1AvalancheThe StarfightersTeenage StranglerSwamp DiamondsPrince of SpaceSquirmThe Million Eyes of SumuruSocial Media:@JustAewchEmail: aewch64@gmail.com

In this episode of Blood Cancer Talks, hosts Eddie, Ashwin, and Raj welcome two distinguished experts to explore the cutting-edge field of circulating tumor DNA (ctDNA) in B-cell lymphomas. Dr. David Russler-Germain, a lymphoma clinician from Siteman Cancer Centre at Washington University in St. Louis, returns as a familiar voice to the podcast audience. Joining him is Dr. Ash Alizadeh, the Moghadam Family Professor of Medicine, Oncology, and Hematology at Stanford University and leader of the Cancer Genomics Program at Stanford Cancer Institute. Dr. Alizadeh has been instrumental in advancing our understanding of lymphomagenesis and lymphoma genetics over the past two decades, pioneering multiple ctDNA techniques that are revolutionizing cancer care. Together, they discuss the transformative potential of ctDNA technology in B-cell lymphomas, particularly DLBCL, covering everything from the technical evolution of biomarker detection to groundbreaking clinical data that may reshape how we monitor and treat these aggressive cancers. Key Discussion Topics1. Genetic Heterogeneity in B-Cell LymphomasComplex genetic landscape of DLBCLImplications for treatment strategiesNeed for personalized approaches 2. Clinical Need for ctDNA in LymphomaWhy ctDNA is needed in aggressive lymphomas:Curative vs. non-curative treatment settingsLimitations of current PET imagingAdditional prognostic information beyond imagingRisk stratification capabilitiesPotential to avoid overtreatmentTherapy adaptation opportunities 3. Challenges in Lymphoma MRD AssessmentWhy lymphoma MRD is more complex than other hematologic malignancies:Differences from acute leukemias, CLL, and myelomaTechnical challenges specific to lymphoid tumorsLower circulating tumor burden compared to liquid tumors 4. ClonoSEQ TechnologyMechanism: Immunoglobulin sequencing approachAdvantages: Established platform with regulatory approvalDisadvantages: Limited sensitivity in peripheral blood, requires adequate tumor sample 5. CAPP-Seq TechnologyFull Name: Cancer Personalized Profiling by Deep SequencingInnovation: Developed ~10 years ago by Dr. Alizadeh's groupMechanism: Targeted sequencing of cancer-specific mutationsAdvantages: High sensitivity, personalized approach 6. PhasED-Seq TechnologyEvolution: Next-generation advancement of CAPP-SeqKey Improvements: Enhanced sensitivity and specificityTechnical Advances: Phased variant detection Clinical Data Highlights1. Remission Assessment by ctDNA in LBCL on 5 prospective studies of frontline anthracycline-based chemo-immunotherapy: https://pubmed.ncbi.nlm.nih.gov/40802906/2. Prospective validation of end of treatment ctDNA-MRD by PhasED-Seq in DLBCL patients from HOVON-902 clinical trial: https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.70003. Korean data on prognostic utility of ctDNA: https://ashpublications.org/blood/article/142/Supplement%201/69/501573 

Where's Scoob and the gang when you need them? It's Circulating the Tapes, the MST3K watchalong podcast on the Aewchcast. On this episode, Aewch doesn't solve the crime, but somehow solves the movie first, as he reviews Teenage Strangler. Plus, the short that drove more people to elope, Is This Love?Watch Teenage Strangler Right Here!The CTT UERL Top Ten!I Accuse My ParentsGodzilla vs Megalon Master Ninja 1AvalancheThe StarFightersSwamp DiamondsPrince of SpaceSquirmThe Million Eyes of SumuruLords of the DeepSocial Media: @JustAewchEmail: aewch64@gmail.com

On this episode of Nailing the Apex 00:00 The Ferrari rumours 18:46 Baku Sim Lap 18:46 Who has the advantage at Baku? 19:26 Will Issac Hadjar be moving to Red Bull? 28:38 Thoughts on the F1 Movie Learn more about your ad choices. Visit megaphone.fm/adchoices

Technology is Dan's worst enemy yet again as he provides updates on Tyler Robinson | aired on Wednesday, September 17th, 2025 on Nashville's Morning News with Dan Mandis. See omnystudio.com/listener for privacy information.

Time now for our daily Tech and Business Report. Today, Google has announced plans to crackdown on the spread of non-consensual images. For more, KCBS Radio anchor Holly Quan spoke with Bloomberg's Janne Knodler.

Talk about here, fishy fishy, It's Circulating the Tapes, the MST3K watchalong podcast on The Aewchcast. On this episode, Aewch completely forgets who is on the heist crew, as he reviews Killer Fish.Watch Killer Fish….on your own copy of the DVD.The CTT UERL Top Ten!I Accuse My ParentsGodzilla vs Megalon Master Ninja 1AvalancheThe StarFightersSwamp DiamondsPrince of SpaceSquirmThe Million Eyes of SumuruLords of the DeepSocial Media: @JustAewchEmail: aewch64@gmail.com

Steve Gruber discusses news and headlines 

Pass the shuriken on the left hand side, it's Circulating the Tapes, the MST3K Watchalong podcast on The AewchCast. In this episode, Aewch needs a skinnier stunt double as he reviews Master Ninja 1.Watch Master Ninja 1 Right Here!The CTT UERL Top Ten!I Accuse My ParentsGodzilla vs MegalonAvalancheThe StarfightersSwamp DiamondsPrince of SpaceSquirmThe Million Eyes of SumuruLords of the DeepThe Crawling EyeSocial Media: @JustAewchEmail: aewch64@gmail.com

Love the episode? Send us a text!In this special episode of Breast Cancer Conversations, host Laura Carfang speaks with Dr. Troso  about the evolving role of DNA testing in breast cancer care. Together, they break down the three main types of testing:Hereditary genetic testing: Identifying inherited mutations such as BRCA1, BRCA2, and PALB2 (among others) that increase cancer risk and influence prevention and treatment decisions.Somatic (tumor) testing: Analyzing mutations within the tumor itself—such as PIK3CA or ESR1 mutations—to guide targeted therapies and manage resistance in advanced disease.Circulating tumor DNA (ctDNA) testing: Also known as a liquid biopsy, this emerging tool uses blood tests to detect cancer DNA fragments. It holds promise for monitoring recurrence, guiding treatment earlier, and advancing clinical trials.Tune into this Special! 

How can conversation become a real driver of circular transformation? In this episode, George Marshall explains why conversations are central to circular change and how to design them to build trust, reach across difference, and motivate action. Circular economy strategies often focus on systems and structures but lasting change only happens when people connect new behaviors to their own identity and values. Without shared understanding and engagement, technical solutions risk staying at the surface. Recorded live at the LOOP Forum 2025, his keynote explores how businesses can move beyond top-down messaging to create real dialogue that activates people at every level of an organisation. This episode is part of our series on the LOOP Forum 2025 highlights, bringing you the key ideas and insights from this year's leading Nordic event on circularity.

Get born to be mild, because it's Circulating the Tapes, the MST3K watchalong podcast on The AewchCast. On this episode, Aewch tosses around more smack than Maxwell's silver hammer as he reviews The Hellcats.Watch The Hellcats Right Here!The CTT UERL Top Ten!I Accuse My ParentsGodzilla vs MegalonAvalancheThe StarfightersSwamp DiamondsPrince of SpaceSquirmThe Million Eyes of SumuruLords of the DeepThe Crawling EyeSocial Media: @JustAewchEmail: aewch64@gmail.com

All bikini but no A-go-go, it's Circulating the Tapes, the MST3K watchalong podcast on The AewchCast. On this episode, what Aewch wouldn't give to work for a cabal of sexy evil women, as he reviews The Million Eyes of Sumuru.Watch The Million Eyes of Sumuru Right Here!The CTT Ultimate Episode Ranking Top 10!I Accuse My ParentsGodzilla vs MegalonAvalancheThe StarfightersSwamp DiamondsPrince of SpaceSquirmLords of the DeepThe Crawling EyeThe Day Time EndedSocial Media: @JustAewchEmail: aewch64@gmail.com

Don't Touch that Connors, it's Circulating the Tapes, the MST3K watchalong Podcast on The AewchCast. On this episode, Aewch goes red, white, and blonde, as he reviews Swamp Diamonds. Plus, the short that gave the A/V club hope, What to Do on a Date.Watch Swamp Diamonds Right Here!The CTT Top Ten!I Accuse My ParentsGodzilla vs MegalonAvalancheThe StarfightersPrince of SpaceSquirmLords of the DeepThe Crawling EyeThe Day Time EndedTeenage CavemanSocial Media: @JustAewchEmail: aewch64@gmail.com

Put on your best polyester skisuit, it's Circulating the Tapes, the MST3K watchalong podcast on The Aewchcast. On this episode, Aewch swears he can tell the difference between real snow and styrofoam boulders as he reviews Avalanche.Watch Avalanche…on your copy of the DVD.The CTT Ultimate Episode Ranking Top Ten List!I Accuse My ParentsGodzilla vs MegalonThe StarfightersPrince of SpaceSquirmLords of the DeepThe Crawling EyeThe Day Time EndedTeenage CavemanRacket GirlsSocial Media: @JustAewchEmail: aewch64@gmail.com

Follow the Rule and listen to Circulating the Tapes, the MST3K watchalong podcast on The Aewchcast. On this episode, Aewch dares to enter the forbidden zone, as he reviews Teenage Caveman. Plus, TWO shorts, the nightmare of safety known as Aquatic Wizards, and the scourge to animals Catching Trouble.Watch Teenage Caveman Right Here!The CTT Ultimate Episode Ranking List!I Accuse My ParentsGodzilla vs MegalonThe StarfightersPrince of SpaceSquirmLords of the DeepThe Crawling EyeThe Day Time EndedRacket GirlsSocial Media: @JustAewchEmail: aewch64@gmail.com

Get your hands on some spiritual Gak, because it's Circulating the Tapes, the MST3K watchalong podcast on The Aewchcast. On this episode, Aewch borrows a mini-sub(Don't worry, there's plenty left), as he reviews Lords of the Deep.Watch Lords of the Deep…on your copy of the DVD.The CTT Ultimate Episode Ranking List!I Accuse My ParentsGodzilla vs MegalonThe StarfightersPrince of SpaceSquirmThe Crawling EyeThe Day Time EndedRacket GirlsSocial Media: @JustAewchEmail: aewch64@gmail.com

BUFFALO, NY – July 24, 2025 – A new #casereport was #published in Volume 16 of Oncotarget on July 23, 2025, titled “Extracorporeal blood filtration leading to tumor growth arrest and reduced analgesic requirements in Stage IV poorly differentiated pancreatic adenocarcinoma: A case report.” In this report, Susanna Ulahannan from the University of Oklahoma Health Sciences Center and colleagues describe the use of extracorporeal blood filtration in a patient with metastatic pancreatic cancer. The patient experienced clinical improvement, reduced pain, and no signs of new tumor growth over 12 months of follow-up. Metastatic pancreatic cancer is difficult to treat and is often diagnosed at an advanced stage. In this case, a 51-year-old woman with stage IV poorly differentiated adenocarcinoma chose not to undergo standard chemotherapy. Instead, she received extracorporeal blood filtration with the Seraph® 100 device, which is designed to remove circulating tumor cells (CTCs) from the bloodstream. CTCs are thought to contribute to the spread of cancer to other organs. “Circulating tumor cells (CTC's) are tumor cells that are shed from the primary tumor and travel via blood or lymphatic system to form micro metastases in distant organs under a suitable environment.“ The patient received between nine and twelve treatments over the course of a year. These treatments were performed both abroad, where the device is approved for this use, and under a clinical protocol in the United States. Medical imaging showed that her disease remained stable, with no new metastases detected. She also reported improvements in appetite, energy levels, and pain control. Her opioid use was reduced by 90%. Blood samples confirmed a drop in CTC levels after treatment. This observation supports the idea that removing CTCs might help limit cancer progression in some patients. However, given that this is a single case report, larger clinical studies are needed to evaluate the effectiveness of this approach. The mechanism behind the patient's pain relief is not fully understood. Authors suggest that it may be related to the reduction of tumor cells or inflammatory molecules in the blood. Researchers noted that pro-inflammatory cytokines, known to influence pain, could also have been affected by the filtration process. This is the first documented case of stable disease and reduced symptoms following CTC filtration in advanced pancreatic cancer. While these findings should not be generalized, they highlight an approach outside standard protocols that should be further explored in clinical research. Future studies will be needed to determine whether this method can contribute to symptom management or disease control in other patients with metastatic pancreatic cancer. DOI - https://doi.org/10.18632/oncotarget.28756 Correspondence to - Susanna Ulahannan - susanna-ulahannan@ouhsc.edu Video short - https://www.youtube.com/watch?v=dro6iUGDrVQ Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28756 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, extracorporeal blood filtration, circulating tumor cells, metastatic pancreatic cancer, seraph 100, OncoBind To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

I'm…getting a…vision…A Podcast called Circulating the Tapes, the MST3K watchalong podcast on The Aewchcast. On this episode, Aewch does a deep dive into some Best Brains history, as he reviews the first episode of MST3K (Sans KTMA), The Crawling Eye. Watch The Crawling Eye Right Here!The CTT Ultimate Episode Ranking List!I Accuse My ParentsGodzilla vs MegalonThe StarfightersPrince of SpaceSquirmThe Day Time EndedRacket GirlsSocial Media: @JustAewchEmail: aewch64@gmail.com

Jeff Grubb is joined by Kat Bailey to start the week. We chat about a banana boatload of Donkey Kong Bananza related stories, the price of the Asus ROG Ally Xbox device getting leaked, EA shelving the Need for Speed franchise, and more stories for your Monday morning!

(SPOILER) Your Daily Roundup covers Big Brother 27 premiering tonight, the rumor mill already starting about one contestant, Jesse from the Valley on a podcast giving his thoughts on Janet, and a new raw dogging challenge on a flight that is more up my alley.       Music written by Jimmer Podrasky (B'Jingo Songs/Machia Music/Bug Music BMI) Ads: ZocDoc – Click on https://zocdoc.com/RealitySteve to find and instantly book a top rated doctor today.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Samira, a breast cancer survivor and CEO of Manta Cares, discusses the latest advancements in cancer treatment with Dr. Doug Blayney at the ASCO conference. They explore the significant impact of exercise on cancer treatment tolerance and survival, the de-escalation of chemotherapy, the introduction of new therapies like SERDs and antibody drug conjugates, and the role of circulating tumor DNA in monitoring cancer recurrence. The conversation emphasizes the importance of patient convenience and self-advocacy in cancer care.About Our Guest:Douglas W. Blayney, MD is a Professor of Medicine (Oncology), Emeritus, former Medical Director of Stanford Cancer Center, and specializes in the treatment of breast cancer. He has a special interest in the quality and value of cancer care. Dr. Blayney is a past president of the American Society of Clinical Oncology (ASCO), a founder of the ASCO Quality Symposium, a co-author of the ASCO value framework descriptions, and instigated the ASCO clinical "big data" effort, which is now CancerLinQ. He received the inaugural Ellen Stovall Award for Leadership in Patient Centered Care from the National Coalition for Cancer Survivorship in 2016. He was previously a Professor of Internal Medicine and Medical Director of the Comprehensive Cancer Center at the University of Michigan, and prior to that practiced and led Wilshire Oncology Medical Group, Inc. a physician owned multidisciplinary oncology practice in southern California. He has expertise on clinical trial development, use of oncology drugs in clinical practice, reimbursement and marketing strategies and information technology use.Chapter Codes00:00 The Impact of Exercise on Cancer Treatment02:00 Interview at ASCO Starts06:00 Advancements in Cancer Treatment: De-escalation and AI11:52 Emerging Therapies: SERDs and Antibody Drug Conjugates18:11 Circulating Tumor DNA: A New Frontier in Monitoring24:01 Convenience in Cancer Care: A Patient-Centric ApproachTakeaways- Regular exercise can increase tolerance to cancer treatments.- Data shows exercise has tangible benefits on survival rates.- De-escalation of chemotherapy is a key focus in cancer treatment.- AI is being integrated into cancer treatment guidelines.- Patients can take proactive steps to improve their health.- Oral SIRDs are emerging as a more convenient treatment option.- Antibody drug conjugates target cancer cells with fewer side effects.- Circulating tumor DNA can help detect cancer recurrence earlier.- Convenience in treatment is becoming a priority for patients.- Competition among treatments may help reduce costs for patients.Tags & Keywords:cancer treatment, ASCO, exercise, AI, SIRDs, antibody drug conjugates, circulating tumor DNA, patient care, chemotherapy, cancer survival, health technologyConnect with Us:Enjoyed this episode? Make sure to subscribe, rate, and review! Follow us on Instagram, Facebook, or Linkedin @mantacares and visit our website at mantacares.com for more episodes and updates.Listen Elsewhere: Website: https://mantacares.com/pages/podcast?srsltid=AfmBOopEP5GJ-Wd2nL-HYAInrwerIVhyJw67salKT-r9Qb_gadBvbHie YouTube: https://youtu.be/UjsAtpbedA8 Spotify: https://open.spotify.com/episode/7HwhjXHZU0ZWWVkXrCSV7V?si=d5e986f0885a4bbb Apple: https://podcasts.apple.com/us/podcast/cervical-cancer-and-hpv-what-you-need-to-know/id1622669098?i=1000710235401 Disclaimer:All content and information provided in connection with Manta Cares is solely intended for informational and educational purposes only. This content and information is not intended to be a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

In the first episode of a special daily series during the 2025 ASCO Annual Meeting, Dr. John Sweetenham discusses the results of 2 studies on the treatment of advanced colorectal cancer plus an additional study exploring the association of Medicaid expansion with cancer survival outcomes. Transcript Dr. John Sweetenham: Hello, and welcome to our special coverage of the 2025 ASCO Annual Meeting on the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham, and I'll be bringing you brief analysis on selected abstracts from each day of the Meeting. My disclosures are available in the transcript of this episode.  Today, I'll be reviewing three abstracts, the first two of which address the treatment of advanced colorectal cancer. Today's first study is Abstract 3501. These data were presented by Dr. Heinz-Josef Lenz from the USC Norris Comprehensive Cancer Center and report on the expanded analysis of the CheckMate-8HW trial. This was a phase 3, international, multicenter trial in patients with MSI-high/MMR-deficient metastatic colorectal cancer, who were randomized between nivolumab (nivo) alone, nivolumab plus ipilumomab (ipi) or investigators' choice of chemotherapy (FOLFOX or FOLFIRI) with or without bevacizumab or cetuximab. The study showed that nivo plus ipi demonstrated superior progression-free survival compared with chemotherapy in the first-line setting and superior progression-free survival compared with nivo alone across all lines of therapy. These results led to the approval of nivo + ipi in the first-line setting in patients with MSI-H/dMMR mCRC in the U.S., the EU, and many other countries.  In today's presentation, Dr. Lenz reported on the expanded analyses of nivo plus ipi versus nivo across all lines of therapy and longer follow-up results for nivo and ipi versus chemo in the first-line setting. With longer follow up (the median is now at 47 months) nivo and ipi continued to show progression-free survival benefit compared with chemotherapy with a median PFS of 54.1 months versus 5.9 months, for a hazard ratio of 0.21.  Additionally, the analysis of the effects on PFS2, defined as the time from randomization to progression after subsequent systemic therapy, start of second subsequent systemic therapy, or death, showed that compared with chemotherapy, first-line nivo and ipi was associated with a 72% reduction in the risk of death or disease progression, despite the fact that 71% of those who progressed following chemotherapy crossed over to receive subsequent immunotherapy. The study also showed that across all lines, nivo and ipi demonstrated superior progression-free survival compared with nivo alone, the median not reached versus 39.3 months, for a hazard ratio of 0.62. No new toxicity signals emerged after further analysis. Most treatment-related adverse events with possible immune etiology were observed within the first six months of therapy. The results for PFS2 are particularly significant. Up to now, there has been some reluctance to use nivo and ipi as first-line therapy, partly because of its toxicity profile and based on the rationale that it would be active after other frontline therapies. The observation in this study that the beneficial effects of nivo and ipi are maintained downstream is compelling. The results suggest that delaying the use of this combination to the second line or later may compromise subsequent PFS and supports the use of nivo and ipi as a standard-of-care frontline option for MSI-H/dMMR metastatic colorectal cancer. Moving on, the next study I'm featuring today is Abstract 3503, presented by Dr. Jeanne Tie from the Peter MacCallum Cancer Centre and the Walter and Eliza Hall Medical Institute of Medical Research from Melbourne, Australia. This study reported the impact of circulating tumor DNA (ctDNA)-guided adjuvant chemotherapy escalation in stage III colon cancer, focused on the primary analysis of the ctDNA-positive cohort from the randomized DYNAMIC-III trial. As background, about 30% of patients with stage III colon cancer will recur following standard-of-care adjuvant therapy with oxaliplatin-based regimens. And current data show that for those patients with high-risk disease, 6 months of chemotherapy is associated with a lower recurrence rate than 3 months. Circulating tumor DNA following initial surgery has been shown to be a strong independent prognostic factor for these patients, but questions remain about how ctDNA can be used for adaptation of treatment. Questions regarding treatment adaptation were addressed in the DYNAMIC-III trials – specifically, does treatment escalation benefit those who are ctDNA positive following surgery, and can therapy be de-escalated for those who are ctDNA negative. The first of these 2 questions – treatment escalation in the positive group – is the subject of this report. One thousand and two patients were randomized in this study, between ctDNA-informed therapy (502) or standard management (500). Of those patients included in the intent to treat cohorts, 129 were ctDNA positive in the ctDNA-informed arm compared with 130 in the standard management arm. Various pre-planned treatment escalation protocols were used, depending on the choice of first-line therapy. With a median follow up of 42.2 months, there was no difference in 3-year relapse free survival between the ctDNA informed group (48%) and the standard management group (52%). There was, however, a highly significant difference in relapse-free survival for patients who cleared ctDNA by the end of treatment compared with those who didn't. The authors concluded that the recurrence risk for this group remains high, at about 50%, after adjuvant therapy and that it increases with higher ctDNA burden, but treatment escalation didn't appear to reduce the recurrence risk. Clearance of ctDNA was associated with a favorable outcome, suggesting that as more effective treatments are developed in the future for this group, ctDNA will likely prove to have major utility. Changing gears now, my final selection for today is Abstract 11006, presented by Dr. Elizabeth Shafer from the American Cancer Society. This study explored the association of Medicaid expansion with 5-year survival after a cancer diagnosis.  Dr. Schafer began her presentation by providing some historical perspective on the impact of the Affordable Care Act on reducing the number of uninsured adults aged less than 65 years in the United States. She then reviewed some recent data on the impact of Medicaid expansion on cancer care, including improved screening rates, improved access to cancer surgery, and an increase in earlier cancer diagnosis. The current study builds on earlier data from the American Cancer Society which showed improved 2-year overall survival for patients with newly diagnosed cancer following Medicaid expansion. The new study reported by Dr. Schafer examined 5-year cause-specific survival in individuals with cancer since Medicaid expansion, analyzed according to cancer type and various demographic and social factors. Using data from more than 813,000 individuals from 26 states that expanded Medicaid compared with more than 610,000 from 12 states that did not, the authors reported that similar improvements in 5-year cause-specific survival were observed in the expansion and the non-expansion states, but when analyzed by other factors, differences in outcome emerged. For example, although similar improvements in survival between expansion and non-expansion states were seen in urban communities, there was a significant improvement of 2.55 percentage points in survival for individuals in rural communities in expansion states compared with those in non-expansion states. Similar trends were observed in high poverty areas, where improvements in survival were superior in expansion versus non-expansion states.  When examined by cancer type, the authors observed greater improvements in 5-year survival for those with pancreatic, lung, and colorectal cancer, possibly due to improvements in screening and early access to treatment.  The authors concluded that those residing in rural and high-poverty areas experienced the most improvement in cause-specific cancer survival following Medicaid expansion. In summary, it's encouraging to see an improving trend in cancer mortality overall, independent of Medicaid expansion, but it's also important to remember that this is yet another study which confirms how implementation of the ACA has improved cancer outcomes and begun to address some of the disparities in cancer care. Join me again tomorrow to hear more top takeaways from ASCO25. And if you value the insights that you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts.   Disclaimer:   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.     Find out more about today's speaker:  Dr. John Sweetenham    Follow ASCO on social media:  @ASCO on Twitter  @ASCO on Bluesky  ASCO on Facebook  ASCO on LinkedIn        Disclosures:  Dr. John Sweetenham:  No relationships to disclose 

Featuring a slide presentation and related discussion from Dr John P Leonard, including the following topics: Five-year analysis of the POLARIX trial of polatuzumab vedotin with R-CHP for previously untreated diffuse large B-cell lymphoma (0:00) Epcoritamab, glofitamab and other bispecific antibodies for large B-cell lymphoma (5:33) Circulating tumor DNA as an early outcome predictor in patients with large B-cell lymphoma receiving second-line lisocabtagene maraleucel in the TRANSFORM study (16:44) The bispecific antibodies mosunetuzumab and odronextamab as initial therapy for follicular lymphoma (FL) (19:27) The Phase III inMIND trial of tafasitamab in combination with lenalidomide/rituximab for recurrent FL (22:58) Updated results from studies of bispecific antibodies and chimeric antigen receptor T-cell therapy for relapsed/refractory FL (24:58) Updates from the Phase III TRIANGLE and ECOG-ACRIN EA4151 trials on the role of autologous stem cell transplant in the treatment of previously untreated mantle cell lymphoma (MCL) (27:48) Novel treatment approaches with Bruton tyrosine kinase inhibitors for patients with newly diagnosed MCL (30:53) CME information and select publications

Join our NEW Community Discord! https://www.discord.gg/podcast Today's topics we cover Epic's unforeseen job at handling cheaters. Topics: 1. Clix has his trio snake him in the final week! 2. Will the next LAN be in Raleigh or France? 3. Will Fortnite Competitive officially support the a new game mode? 4. Tune into the Comp awards! https://x.com/CompAwardsFN Follow Us On Twitter: MonsterDface - @MonsterDface Somebodysgun - @Somebodysgun LifeWithPanda - @LifewPanda  Email all of your complaints to us on twitter. Don't forget to leave us a comment!